Anales de la RANM

80 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 TERAPIA INICIAL DEL MIELOMA MÚLTIPE Fernández-Rañada JM An RANM. 2023;140(01):72 - 80 13. Gay F, Musto P, Rota-Scalabrini D et al. Car- filzomib with cyclosphosphamide and dexa- methasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalido- mide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label pase 2 trial. Lancet Oncol. 2021; 22(12): 1705-1720. 14. Moreau P, Attal M, Hulin C et al. Bortezo- mib, thalidomide, and dexamethasone with or without daratumumab before and after au- tologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, pase 3 study. Lancet. 2019; 394(10192): 29-38. Erratum in: Lancet. 2019 Jun 14: PMID: 31171419. 15. Sborov MD et al. International Myeloma So- ciety. 2022. 16. Attal M, Lauwers-Cances V, Marit G et al. Le- nalidomide maintenance after stem-cell trans- plantation for multiple myeloma. N Engl J Med. 2012; 366(19): 1782-1791. 17. McCarthy PL, Holstein SA, Petrucci MT et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin On- col. 2017; 35(29): 3279-3289. 18. McCarthy PL, Owzar K, Hofmeister CCet al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19): 1770-1781. 19. Dimopoulos MA, Moreau P, Terpos E et al. Multiple myeloma: EHA-ESMO Clinical Prac- tice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(3): 309-322. Erratum in: Ann Oncol. 2022 ;33(1):117. PMID: 33549387. 20. Durie BGM, Hoering A, Sexton Ret al. Longer term follow-up of the randomized phase III trial SWOG S0777: Bortezomib, lenalidomide and dexametasone vs. lenalidomide and dexa- methasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020; 10(5): 53. 21. Mateos MV, Dimopoulos MA, Cavo M et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378(6): 518-528. 22. Mateos MV, Cavo M, Blade J et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagno- sed multiple myeloma (ALCYONE): a rando- mised, open-label, phase 3 trial. Lancet. 2020; 395(10218): 132-141. 23. Facon T, Kumar S, Plesner T et al. Daratumu- mab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019; 380(22): 2014-2115. 24. Facon T, Kumar SK, Plesner Tet al. Daratumumab, lenalidomide, and dexamethasone versus lenali- domide and dexamethasone alone in newly diag- nosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(11): 1582-1596. Si desea citar nuestro artículo: Fernández-Rañada JM. Terapia inicial del mieloma múltipe (MM). An RANM. 2023;140(01): 72– 80. DOI: 10.32440/ar.2023.140.01 . rev08